Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study

Woitas, Rainer P.; Kleber, Marcus E.; Meinitzer, Andreas; Grammer, Tanja B.; Silbernagel, Günther; Pilz, Stefan; Tomaschitz, Andreas; Weihrauch, Gisela; Dobnig, Harald; März, Winfried; Scharnagl, Hubert

doi:10.1016/j.atherosclerosis.2013.04.027

Cited by 40 publications

(42 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…rs2074381 of ALPK1 was significantly associated with CAD and ischemic stroke, with the GG genotype being protective against these conditions. These previous observations (27,41,(43)(44)(45)(46)(47)(48)(49)(50)(51)(52) and our present results suggest that ALPK1 may contribute to the development of CAD and ischemic stroke through the acceleration of vascular inflammation, although the molecular mechanisms underlying the role of rs2074381 of ALPK1 in the pathogenesis of CAD and ischemic stroke remain unknown.…”

Section: Discussionsupporting

confidence: 42%

“…The serum concentration of cystatin C was thus associated with those of C-reactive protein and fibrinogen in 990 subjects with coronary heart disease in the Heart and Soul Study (43), as well as in subjects with renal dysfunction in the Cardiovascular Health Study (44). Furthermore, the serum concentration of cystatin C was associated with the prevalence and severity of CAD (45)(46)(47), the risk of secondary cardiovascular events (48,49) and cardiovascular mortality (50). Cystatin C was also associated with ischemic and hemorrhagic stroke (51) and subclinical cerebral infarction (52).…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study

et al. 2015

View full text Add to dashboard Cite

Abstract. Our previous studies identified nine genes and chromosomal region 3q28 as susceptibility loci for myocardial infarction, ischemic stroke or chronic kidney disease by genome-wide or candidate gene association studies. As coronary artery disease (CAD) and ischemic stroke may share genetic architecture, certain genetic variants may confer susceptibility to the two diseases. The present study examined the association of 13 polymorphisms at these 10 loci with the prevalence of CAD or ischemic stroke in community-dwelling individuals, with the aim of identifying genetic variants that confer susceptibility to the two conditions. Study subjects (170 with CAD, 117 with ischemic stroke and 5,718 controls) were recruited to the Inabe Health and Longevity Study, a longitudinal genetic epidemiological study of atherosclerotic, cardiovascular and metabolic diseases. The subjects were recruited from individuals who visited for an annual health checkup and they were followed up each year (mean follow-up period, 5 years). Longitudinal analysis with a generalized estimating equation, and with adjustment for age, gender, body mass index, smoking status, the prevalence of hypertension, diabetes mellitus and dyslipidemia and the serum concentration of creatinine, revealed that rs2074380 (G→A) and rs2074381 (A→G) of the α-kinase 1 (ALPK1) gene and rs8089 (T→G) of the thrombospondin 2 (THBS2) gene were significantly (P<2x10 -16 ) associated with the prevalence of CAD, with the AA genotype of rs2074380 and GG genotypes of rs2074381 and rs8089 being protective against this condition. Similar analysis revealed that rs9846911 (A→G) at chromosome 3q28, rs2074381 of ALPK1, rs8089 of THBS2 and rs6046 (G→A) of the coagulation factor VII gene were significantly (P<2x10 -16 ) associated with the prevalence of ischemic stroke, with the GG genotypes of rs9846911, rs2074381 and rs8089 and the AA genotype of rs6046 being protective against this condition. ALPK1 and THBS2 may thus be susceptibility loci for CAD and ischemic stroke. IntroductionCoronary artery disease (CAD) is an important clinical problem due to its large contribution to mortality. In the United States, the total number of individuals affected by CAD or myocardial infarction (MI) was 15.5 and 7.6 million, respectively, in 2012. The annual incidence of new or recurrent MI and fatal CAD was 935,000, with an annual mortality of 375,295 from these conditions, in 2011 (1). Despite recent advances in therapy, such as drug-eluting stents (2) for acute coronary syndrome, CAD remains the leading cause of fatality in the United States (1). Disease prevention is an important strategy for reducing the overall burden of CAD and the identification of biomarkers for disease risk is key for risk prediction and potential intervention to reduce the chance of future coronary events.Stroke is a complex multifactorial disorder that is believed to result from an interaction between the genetic background of an individual and various environmental factors. It is a common and serious condition, w...

show abstract

Section: Discussionsupporting

confidence: 42%

Section: Discussionmentioning

confidence: 96%

Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…11 The concentration of CysC was strongly associated with long-term all-cause and cardiovascular mortality in subjects referred for coronary angiography, irrespective of the renal function status based on creatinine measurements. 23 However, the literature describing the role of CysC in COPD is sparse, and few studies have addressed this issue to date. In China, Zhang et al 14 reported that high CysC levels were directly associated with decreased lung function in elderly Chinese men with COPD.…”

Section: Discussionmentioning

confidence: 99%

Cystatin C as a Predictor of In-Hospital Mortality After Exacerbation of COPD

Zhou

et al. 2016

Respir Care

View full text Add to dashboard Cite

BACKGROUND: COPD is associated with cardiovascular and renal dysfunction. Cystatin C (CysC) is a biomarker of renal function and an independent risk factor for all-cause and cardiovascular mortality among elderly persons. The aim of the study was to examine the prognostic role of CysC for in-hospital mortality in subjects with a COPD exacerbation. METHODS: Upon admission, serum CysC levels and arterial blood gas analysis from 477 subjects with a COPD exacerbation were measured. Clinical characteristics were also recorded. A receiver operating characteristic curve analysis was used to determine the level of CysC that discriminated survivors from nonsurvivors. Univariate and multiple logistic regression analyses were used to identify the risk factors for in-hospital mortality. To reduce the influence of confounders, subgroup analyses were performed according to the comorbidities, including states of heart failure, renal dysfunction, and pH, P aCO 2 , and P aO 2 levels. RESULTS: During the in-hospital period, 59 subjects died, and 418 subjects recovered. The decedent group showed lower pH (7.27 ؎ 0.17 vs 7.38 ؎ 0.06, P < .001), higher CysC (2.21 ؎ 1.05 mg/L vs 1.39 ؎ 0.54 mg/L, P < .001), higher P aCO 2 (77 ؎ 39 mm Hg vs 48 ؎ 14 mm Hg, P < .001), and lower P aO 2 (74 ؎ 32 mm Hg vs 84 ؎ 26 mm Hg, P < .001) levels. The area under the receiver operating characteristic curve for the CysC prediction of death was 0.77 (95% CI 0.70 -0.84). CysC values >1.59 mg/L were associated with significantly higher inhospital mortality (relative risk ‫؍‬ 5.49, 95% CI 3.24 -9.32, P < .001). Multiple logistic regression analysis showed that pH <7.20, CysC >1.59 mg/L, and heart failure were independent predictors of in-hospital mortality. The subgroup analysis showed that the comorbid states of renal dysfunction, congestive heart failure, and the levels of pH, P aCO 2 , and P aO 2 did not alter the conclusion that CysC was a mortality risk factor for subjects with a COPD exacerbation. CONCLUSION: CysC was a strong and independent risk factor for hospital mortality secondary to COPD exacerbation.

show abstract

“…Elevated CysC levels also predicted mortality in elderly HF patients [65], and were found to be associated with all-cause and cardiovascular mortality in CAD patients referred for coronary angiography in a recent study [66]. A study on diabetic cohort also showed that CysC-based definition of CKD predicted higher risk for cardiovascular events [67].…”

Section: High-risk Populationsmentioning

confidence: 94%

“…A recent study on patients referred to coronary angiography showed that CysC improved the risk reclassification beyond the established risk factors [66]. The net reclassification improvement (NRI) for cardiovascular mortality was 30.1% …”

Section: Cysc and Cardiovascular Risk Reclassificationmentioning

confidence: 97%

Novel biomarkers with potential for cardiovascular risk reclassification

et al. 2016

View full text Add to dashboard Cite

Precise estimation of the absolute risk for CVD events is necessary when making treatment recommendations for patients. A number of multivariate risk models have been developed for estimation of cardiovascular risk in asymptomatic individuals based upon assessment of multiple variables. Due to the inherent limitation of risk models, several novel risk markers including serum biomarkers have been studied in an attempt to improve the cardiovascular risk prediction above and beyond the established risk factors. In this review, we discuss the role of underappreciated biomarkers such as red cell distribution width (RDW), cystatin C (cysC), and homocysteine (Hcy) as well as imaging biomarkers in cardiovascular risk reclassification, and highlight their utility as additional source of information in patients with intermediate risk.

show abstract

Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study

Cited by 40 publications

References 33 publications

Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study

Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study

Cystatin C as a Predictor of In-Hospital Mortality After Exacerbation of COPD

Novel biomarkers with potential for cardiovascular risk reclassification

Contact Info

Product

Resources

About